Rank #1982GRTX

Galera Therapeutics, Inc.

$0.03

18.96% (Daily)

Market Cap

$1.89M

Revenue

$N/A

Rank by MCap

#1982

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. J. Mel Sorensen M.D.

Headquarters

Malvern, PA

Employees

About Galera Therapeutics, Inc.

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganes...